MELE, GIUSEPPE
 Distribuzione geografica
Continente #
EU - Europa 16
Totale 16
Nazione #
IT - Italia 16
Totale 16
Città #
Rome 10
Gioiosa Ionica 6
Totale 16
Nome #
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, file 5e146688-8155-4947-b4c6-a2cc0f6836c3 4
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients, file 730e8026-212b-4a79-b648-e4d094ddcbcb 4
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, file 83e09d9e-4612-4446-88a1-01a710493976 4
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file 85b4b71b-b9a2-4815-a6d4-f3b29133abc6 2
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials, file b480e67a-d732-4a6e-b442-eb4c33a2857f 2
Totale 16
Categoria #
all - tutte 16
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202416 0 0 0 0 0 10 6 0 0 0 0 0
Totale 16